The Liberals handed out tens of millions of dollars to high priced consultants while the very Canadians this program was ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous ...

CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.

Discover why India is emerging as the global center for Global Business Services (GBS) and Global Capability Centers (GCCs), driven by a skilled workforce, advanced technologies, and the rise of ...

Read more about CIDP clinical features “Rather than relying on a single PROM, a combination of PROMs may be necessary to comprehensively capture all relevant aspects of HRQoL for patients with GBS and ...

If you or anyone you know is experiencing symptoms of CIDP, GBS or MMN, or if you would like to see more information about how you can donate, visit the GBS CIDP Foundation International website.

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 DataNVG-2089 is a recombinant Fc fusion protein designed to replicate key ...

For more information about GBS and CIDP Awareness Month and how to get involved, visit www.gbs-cidp.org or contact David Edwards at (202) 771-5222 or [email protected].

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...

Figure 1. Guillain-Barré definitions and time course: TRF defines the situation when patients with GBS, previously stabilized or improved with treatment, show clinical deterioration within two months ...

GBS said that this “regulatory anomaly” could be cured if that broadcaster could use a distributed transmission system focused on a full-service “reference coordinates” established by the broadcaster.